Dietary approaches and supplements in the prevention of cognitive decline and Alzheimer’s disease

Current Pharmaceutical Design

Volumn 22, Issue 6, 2016, Pages 688-700

  Dominguez, Ligia J ^a   Barbagallo, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Aging; Alzheimer; Cognitive decline; Diet; Inflammation; Nutrition; Oxidative stress; Supplement

Indexed keywords

CAFFEINE; CURCUMIN; EPIGALLOCATECHIN GALLATE; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; LEVACECARNINE; MAGNESIUM; OMEGA 3 FATTY ACID; PHYTOESTROGEN; RESVERATROL; VITAMIN; PLANT MEDICINAL PRODUCT;

ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; CALORIC RESTRICTION; CHRONIC INFLAMMATION; COGNITIVE DEFECT; DIET; DIET SUPPLEMENTATION; FEEDING BEHAVIOR; FOOD COMPOSITION; GARLIC; GINKGO BILOBA; INSULIN RESISTANCE; KETOGENIC DIET; LOW COPPER DIET; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; OBESITY; OKINAWA DIET; OXIDATIVE STRESS; PALEOLITHIC DIET; PRIORITY JOURNAL; TEA; THROMBOSIS; VEGETARIAN DIET; VITAMIN SUPPLEMENTATION; COGNITION DISORDERS; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; HUMAN; IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME;

ALZHEIMER DISEASE; COGNITION DISORDERS; DIET THERAPY; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; PLANT PREPARATIONS; TREATMENT OUTCOME; VITAMINS;

EID: 84958234083     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151204000733     Document Type: Article

References (183)

1. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014; 10: e47-92.
2. Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet 2015; 385: 549-62.
3. Mathers CD, Stevens GA, Boerma T, White RA, Tobias MI. Causes of international increases in older age life expectancy. Lancet 2015; 385: 540-8.
4. Feldman HH, Haas M, Gandy S, et al. Alzheimer's disease research and development: A call for a new research roadmap. Ann N Y Acad Sci 2014; 1313: 16.
5. Halil M, Cemal KM, Emin KM, Yesil Y, Cruz JAJ. Cognitive aspects of frailty: Mechanisms behind the link between frailty and cognitive impairment. J Nutr Health Aging 2015; 19: 276-83.
6. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of alzheimer's disease: An analysis of population-based data. Lancet Neurol 2014; 13: 788-94.
7. Hakim AM. Perspective: Silent, but preventable, perils. Nature 2014; 510: S12.
8. Meydani M. Antioxidants and cognitive function. Nutr Rev 2001; 59: S75-80.
9. Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: The battle of the titans. Brain Res Rev 2007; 56: 443-71.
10. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr 2008; 138: 2510-4.
11. Jacobs DR, Jr., Orlich MJ. Diet pattern and longevity: Do simple rules suffice? A commentary. Am J Clin Nutr 2014; 100 Suppl 1: 313S-9S.
12. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and alzheimer's disease. Lancet Neurol 2011; 10: 187-98.
13. Mao P, Reddy PH. Aging and amyloidbeta-induced oxidative DNA damage and mitochondrial dysfunction in alzheimer's disease: Implications for early intervention and therapeutics. Biochim Biophys Acta 2011; 1812: 1359-70.
14. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in alzheimer's disease. Lancet Neurol 2015; 14: 388-405.
15. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and m2 microglia: The good, the bad, and the inflamed. J Neuroinflamm 2014; 11: 98.
16. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
17. Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in alzheimer's disease measured by positron emission tomography with [11c]daa1106. Biol Psychiatry 2008; 64: 835-41.
18. Yuste JE, Tarragon E, Campuzano CM, Ros-Bernal F. Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci 2015; 9: 322.
19. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in alzheimer's disease. J Alzheimers Dis 2012; 32: 599-608.
20. Bacchetti T, Vignini A, Giulietti A, et al. Higher levels of oxidized low density lipoproteins in alzheimer's disease patients: Roles for platelet activating factor acetyl hydrolase and paraoxonase-1. J Alzheimers Dis 2015; 46: 179-86.
21. de la Torre JC. Vascular risk factors: A ticking time bomb to alzheimer's disease. Am J Alzheimers Dis Other Demen 2013; 28: 551-9.
22. Morley JE. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci 2004; 59: 139-42.
23. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the united states, 2003-2012. JAMA 2015; 313: 1973-4.
24. Sepulveda J, Murray C. The state of global health in 2014. Science 2014; 345: 1275-8.
25. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: A decade of body mass index, alzheimer's disease, and dementia. J Alzheimers Dis 2015; 43: 739-55.
26. Jahangiri A, Wilson PG, Hou T, Brown A, King VL, Tannock LR. Serum amyloid a is found on apo-b-containing lipoproteins in obese humans with diabetes. Obesity (Silver Spring) 2013; 21: 993-6.
27. Gustafson DR, Karlsson C, Skoog I, Rosengren L, Lissner L, Blennow K. Mid-life adiposity factors relate to blood-brain barrier integrity in late life. J Intern Med 2007; 262: 643-50.
28. Kanoski SE, Zhang Y, Zheng W, Davidson TL. The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J Alzheimers Dis 2010; 21: 207-19.
29. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015; 23: 512-8.
30. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: Insights to the role of macrophage and t-cell accumulation in adipose tissue. Proc Nutr Soc 2011; 70: 408-17.
31. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and alzheimer's disease: A meta-analysis. J Gerontol A Biol Sci Med Sci 2013; 68: 433-40.
32. Velloso LA, Folli F, Saad MJ. Tlr4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocr Rev 2015; 36: 245-71.
33. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
34. Miller AA, Spencer SJ. Obesity and neuroinflammation: A pathway to cognitive impairment. Brain Behav Immun 2014; 42: 10-21.
35. Erion JR, Wosiski-Kuhn M, Dey A, et al. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci 2014; 34: 2618-31.
36. Tucsek Z, Toth P, Sosnowska D, et al. Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: Effects on expression of genes involved in beta-amyloid generation and alzheimer's disease. J Gerontol A Biol Sci Med Sci 2014; 69: 1212-26.
37. Liang J, Matheson BE, Kaye WH, Boutelle KN. Neurocognitive correlates of obesity and obesity-related behaviors in children and adolescents. Int J Obes (Lond) 2014; 38: 494-506.
38. Calder PC, Ahluwalia N, Brouns F, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106 Suppl 3: S5-78.
39. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol 2013; 719: 170-9.
40. Geijselaers SL, Sep SJ, Stehouwer CD, Biessels GJ. Glucose regulation, cognition, and brain mri in type 2 diabetes: A systematic review. Lancet Diabetes Endocrinol 2015; 3: 75-89.
41. Kelly KR, Haus JM, Solomon TP, et al. A low-glycemic index diet and exercise intervention reduces tnf(alpha) in isolated mononuclear cells of older, obese adults. J Nutr 2011; 141: 1089-94.
42. Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 2011; 68: 743-52.
43. Martinez-Vicente M. Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation. Semin Cell Dev Biol 2015; 40: 115-26.
44. Jaeger PA, Wyss-Coray T. Beclin 1 complex in autophagy and alzheimer disease. Arch Neurol 2010; 67: 1181-4.
45. Martinez de Morentin PB, Martinez-Sanchez N, Roa J, et al. Hypothalamic mTOR: the rookie energy sensor. Curr Mol Med 2014; 14: 3-21.
46. Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: The physicians' health study II. Arch Intern Med 2007; 167: 2184-90.
47. Ford AH, Flicker L, Alfonso H, et al. Vitamins b(12), b(6), and folic acid for cognition in older men. Neurology 2010; 75: 1540-7.
48. Wald DS, Kasturiratne A, Simmonds M. Effect of folic acid, with or without other b vitamins, on cognitive decline: Meta-analysis of randomized trials. Am J Med 2010; 123: 522-7 e522.
49. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin b-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the beyond ageing project: A randomized controlled trial. Am J Clin Nutr 2012; 95: 194-203.
50. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. A randomized trial of vitamin e supplementation and cognitive function in women. Arch Intern Med 2006; 166: 2462-8.
51. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, et al. Dementia and alzheimer's disease in community-dwelling elders taking vitamin c and/or vitamin e. Ann Pharmacother 2005; 39: 2009-14.
52. Maxwell CJ, Hicks MS, Hogan DB, Basran J, Ebly EM. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 2005; 20: 45-51.
53. Morris MC, Schneider JA, Li H, et al. Brain tocopherols related to alzheimer's disease neuropathology in humans. Alzheimers Dement 2015; 11: 32-9.
54. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin d and cognitive impairment in the elderly U.S. Population. J Gerontol A Biol Sci Med Sci 2011; 66: 59-65.
55. Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin d supplementation and cognitive impairment in the women's health initiative. J Am Geriatr Soc 2012; 60: 2197-205.
56. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. Neurology 2004; 63: 1705-7.
57. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin e, vitamin c, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The women's antioxidant and cardiovascular study. Circulation 2009; 119: 2772-80.
58. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 2005; 32: 89-103.
59. Little SJ, Lynch MA, Manku M, Nicolaou A. Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: A lipidomic analysis. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 155-62.
60. Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (lcpufa) from genesis to senescence: The influence of lcpufa on neural development, aging, and neurodegeneration. Prog Lipid Res 2014; 53: 1-17.
61. Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME. Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease. Brain Res 2015; 1597: 220-46.
62. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or alzheimer disease: A complex association. Nat Clin Pract Neurol 2009; 5: 140-52.
63. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with b vitamins and long-chain omega-3 fatty acids: Ancillary findings from the su.Fol.Om3 randomized trial. Am J Clin Nutr 2011; 94: 278-86.
64. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 2008; 71: 430-8.
65. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish-oil supplementation on mental well-being in older subjects: A randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88: 706-13.
66. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 2012; 6: CD005379.
67. Qin B, Plassman BL, Edwards LJ, Popkin BM, Adair LS, Mendez MA. Fish intake is associated with slower cognitive decline in chinese older adults. J Nutr 2014; 144: 1579-85.
68. Barbagallo M, Dominguez LJ. Magnesium and aging. Curr Pharm Des 2010; 16: 832-9.
69. Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. Mol Aspects Med 2005; 26: 363-78.
70. Hans CP, Chaudhary DP, Bansal DD. Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats. Magnes Res 2003; 16: 13-19.
71. Manuel Y, Keenoy B, Moorkens G, Vertommen J, Noe M, Neve J, De Leeuw I. Magnesium status and parameters of the oxidant- antioxidant balance in patients with chronic fatigue: Effects of supplementation with magnesium. J Am Coll Nutr 2000; 19: 374-82.
72. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987; 7: 369-79.
73. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. Magnes Res 2009; 22: 235-46.
74. Alvarez-Leefmans FJ, Giraldez F, Gamino SM. Intracellular free magnesium in excitable cells: Its measurement and its biologic significance. Can J Physiol Pharmacol 1987; 65: 915-25.
75. Altura BT, Altura BM. Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. Neurosci Lett 1980; 20: 323-7.
76. Lemke MR. Plasma magnesium decrease and altered calcium/magnesium ratio in severe dementia of the alzheimer type. Biol Psychiatry 1995; 37: 341-3.
77. Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ. Altered ionized magnesium levels in mild-to-moderate alzheimer's disease. Magnes Res 2011; 24: S115-21.
78. Cilliler AE, Ozturk S, Ozbakir S. Serum magnesium level and clinical deterioration in alzheimer's disease. Gerontology 2007; 53: 419-22.
79. Durlach J. Magnesium depletion and pathogenesis of alzheimer's disease. Magnes Res 1990; 3: 217-8.
80. Glick JL. Dementias: The role of magnesium deficiency and an hypothesis concerning the pathogenesis of alzheimer's disease. Med Hypotheses 1990; 31: 211-25.
81. Ozturk S, Cillier AE. Magnesium supplementation in the treatment of dementia patients. Med Hypotheses 2006; 67: 1223-5.
82. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The indian solid gold. Adv Exp Med Biol 2007; 595: 75.
83. Ganguli M, Chandra V, Kamboh MI, et al. Apolipoprotein e polymorphism and alzheimer disease: The indo-us cross-national dementia study. Arch Neurol 2000; 57: 824-30.
84. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006; 164: 898-906.
85. Cheng AL, Hsu CH, Lin JK, et al. Phase i clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
86. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with alzheimer disease. J Clin Psychopharmacol 2008; 28: 110-3.
87. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 2012; 4: 43.
88. Hishikawa N, Takahashi Y, Amakusa Y, et al. Effects of turmeric on alzheimer's disease with behavioral and psychological symptoms of dementia. Ayu 2012; 33: 499-504.
89. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and alzheimer's disease. J Pharmacol Exp Ther 2008; 326: 196-208.
90. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA 2009; 302: 2663-70.
91. Owen L, Sunram-Lea SI. Metabolic agents that enhance atp can improve cognitive functioning: A review of the evidence for glucose, oxygen, pyruvate, creatine, and l-carnitine. Nutrients 2011; 3: 735-55.
92. Malaguarnera M, Vacante M, Avitabile T, Cammalleri L, Motta M. L-carnitine supplementation reduces oxidized ldl cholesterol in patients with diabetes. Am J Clin Nutr 2009; 89: 71-6.
93. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl l-carnitine (alc) treatment in elderly patients with fatigue. Arch Gerontol Geriatr 2008; 46: 181-90.
94. Soni M, Rahardjo TB, Soekardi R, et al. Phytoestrogens and cognitive function: A review. Maturitas 2014; 77: 209-20.
95. Alekel DL, Genschel U, Koehler KJ, et al. Soy isoflavones for reducing bone loss study: Effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women. Menopause 2015; 22: 185-97.
96. Handa RJ, Mani SK, Uht RM. Estrogen receptors and the regulation of neural stress responses. Neuroendocrinology 2012; 96: 111-8.
97. Jackson RL, Greiwe JS, Schwen RJ. Emerging evidence of the health benefits of s-equol, an estrogen receptor beta agonist. Nutr Rev 2011; 69: 432-48.
98. Henderson VW, St John JA, Hodis HN, et al. Long-term soy isoflavone supplementation and cognition in women: A randomized, controlled trial. Neurology 2012; 78: 1841-8.
99. Einother SJ, Martens VE. Acute effects of tea consumption on attention and mood. Am J Clin Nutr 2013; 98: S1700-8.
100. Feng L, Li J, Ng TP, Lee TS, Kua EH, Zeng Y. Tea drinking and cognitive function in oldest-old chinese. J Nutr Health Aging 2012; 16: 754-8.
101. Chen D, Milacic V, Chen MS, et al. Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol 2008; 23: 487-96.
102. Song J, Xu H, Liu F, Feng L. Tea and cognitive health in late life: Current evidence and future directions. J Nutr Health Aging 2012; 16: 31-4.
103. Perez-Jimenez J, Hubert J, Hooper L, et al. Urinary metabolites as biomarkers of polyphenol intake in humans: A systematic review. Am J Clin Nutr 2010; 92: 801-9.
104. Jayasena T, Poljak A, Smythe G, Braidy N, Munch G, Sachdev P. The role of polyphenols in the modulation of sirtuins and other pathways involved in alzheimer's disease. Ageing Res Rev 2013; 12: 867-83.
105. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
106. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 2015; 1852: 1071-113.
107. Kim D, Nguyen MD, Dobbin MM, et al. Sirt1 deacetylase protects against neurodegeneration in models for alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-79.
108. Dal-Pan A, Pifferi F, Marchal J, Picq JL, Aujard F. Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS One 2011; 6: e16581.
109. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-7.
110. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 2014; 34: 7862-70.
111. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr Pharm Des 2013; 19: 6064-93.
112. Ray B, Chauhan NB, Lahiri DK. The "aged garlic extract:" (age) and one of its active ingredients s-allyl-l-cysteine (sac) as potential preventive and therapeutic agents for alzheimer's disease (ad). Curr Med Chem 2011; 18: 3306-13.
113. Jeong JH, Jeong HR, Jo YN, Kim HJ, Shin JH, Heo HJ. Ameliorating effects of aged garlic extracts against abeta-induced neurotoxicity and cognitive impairment. BMC Complement Altern Med 2013; 13: 268.
114. Kumar S. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin. Indian J Pharmacol 2015; 47: 444-6.
115. Nooyens AC, Bueno-de-Mesquita HB, van Boxtel MP, van Gelder BM, Verhagen H, Verschuren WM. Fruit and vegetable intake and cognitive decline in middle-aged men and women: The doetinchem cohort study. Br J Nutr 2011; 106: 752-61.
116. Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit 2003; 9: BR325-30.
117. Arendash GW, Mori T, Cao C, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged alzheimer's disease mice. J Alzheimers Dis 2009; 17: 661-80.
118. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in pka signaling and jnk and erk activities in the striatum and cortex of alzheimer's transgenic mice. Brain Res 2011; 1417: 127-36.
119. van Gelder BM, Buijsse B, Tijhuis M, et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: The fine study. Eur J Clin Nutr 2007; 61: 226-32.
120. Cao C, Loewenstein DA, Lin X, et al. High blood caffeine levels in mci linked to lack of progression to dementia. J Alzheimers Dis 2012; 30: 559-72.
121. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: A population-based caide study. J Alzheimers Dis 2009; 16: 85-91.
122. Gelber RP, Petrovitch H, Masaki KH, Ross GW, White LR. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis 2011; 23: 607-15.
123. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: Systematic review and meta-analysis. J Alzheimers Dis 2010; 20 Suppl 1: S187-204.
124. Santos C, Lunet N, Azevedo A, de Mendonca A, Ritchie K, Barros H. Caffeine intake is associated with a lower risk of cognitive decline: A cohort study from portugal. J Alzheimers Dis 2010; 20 Suppl 1: S175-85.
125. Ritchie K, Carriere I, de Mendonca A, et al. The neuroprotective effects of caffeine: A prospective population study (the three city study). Neurology 2007; 69: 536-45.
126. Laitala VS, Kaprio J, Koskenvuo M, Raiha I, Rinne JO, Silventoinen K. Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 2009; 90: 640-6.
127. Arab L, Biggs ML, O'Meara ES, Longstreth WT, Crane PK, Fitzpatrick AL. Gender differences in tea, coffee, and cognitive decline in the elderly: The cardiovascular health study. J Alzheimers Dis 2011; 27: 553-66.
128. Scheltens P. Nutrition and dementia. Eur J Neurol 2009; 16 Suppl 1:3-4.
129. Singh B, Parsaik AK, Mielke MM, et al. Association of mediterranean diet with mild cognitive impairment and alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 2014; 39: 271-82.
130. Alles B, Samieri C, Feart C, Jutand MA, Laurin D, Barberger-Gateau P. Dietary patterns: A novel approach to examine the link between nutrition and cognitive function in older individuals. Nutr Res Rev 2012; 25: 207-22.
131. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189-96.
132. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009; 461: 895-7.
133. Huijbregts PP, Feskens EJ, Rasanen L, et al. Dietary patterns and cognitive function in elderly men in finland, italy and the netherlands. Eur J Clin Nutr 1998; 52: 826-31.
134. Correa Leite ML, Nicolosi A, Cristina S, Hauser WA, Nappi G. Nutrition and cognitive deficit in the elderly: A population study. Eur J Clin Nutr 2001; 55: 1053-8.
135. Shatenstein B, Ferland G, Belleville S, et al. Diet quality and cognition among older adults from the nuage study. Exp Gerontol 2012; 47: 353-60.
136. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 2011; 93: 601-7.
137. Wengreen HJ, Neilson C, Munger R, Corcoran C. Diet quality is associated with better cognitive test performance among aging men and women. J Nutr 2009; 139: 1944-9.
138. Bach-Faig A, Berry EM, Lairon D, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr 2011; 14: 2274-84.
139. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a mediterranean diet and survival in a greek population. N Engl J Med 2003; 348: 2599-608.
140. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med 2013; 368: 1279-90.
141. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. JAMA Intern Med 2015; 175: 1094-103.
142. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: The predimed-navarra randomised trial. J Neurol Neurosurg Psychiatry 2013; 84: 1318-25.
143. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for alzheimer's disease. Ann Neurol 2006; 59: 912-21.
144. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and alzheimer disease mortality. Neurology 2007; 69: 1084-93.
145. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66: 216-25.
146. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of alzheimer disease. JAMA 2009; 302: 627-37.
147. Gu Y, Luchsinger JA, Stern Y, Scarmeas N. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of alzheimer's disease. J Alzheimers Dis 2010; 22: 483-92.
148. Feart C, Samieri C, Rondeau V, et al. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. JAMA 2009; 302: 638-48.
149. Feart C, Torres MJ, Samieri C, et al. Adherence to a Mediterranean diet and plasma fatty acids: Data from the bordeaux sample of the three-city study. Br J Nutr 2011; 106: 149-58.
150. Solfrizzi V, Panza F, Frisardi V, et al. Diet and alzheimer's disease risk factors or prevention: The current evidence. Expert Rev Neurother 2011; 11: 677-708.
151. Cherbuin N, Anstey KJ. The mediterranean diet is not related to cognitive change in a large prospective investigation: The path through life study. Am J Geriatr Psychiatry 2012; 20: 635-9.
152. Gardener S, Gu Y, Rainey-Smith SR, et al.Adherence to a mediterranean diet and alzheimer's disease risk in an australian population. Transl Psychiatry 2012; 2: e164.
153. Yannakoulia M, Kontogianni M, Scarmeas N. Cognitive health and mediterranean diet: Just diet or lifestyle pattern? Ageing Res Rev 2015; 20: 74-8.
154. Miyagi S, Iwama N, Kawabata T, Hasegawa K. Longevity and diet in okinawa, japan: The past, present and future. Asia Pac J Public Health 2003; 15 Suppl: S3-9.
155. Willcox DC, Willcox BJ, Todoriki H, Suzuki M. The okinawan diet: Health implications of a low-calorie, nutrient-dense, antioxidant-rich dietary pattern low in glycemic load. J Am Coll Nutr 2009; 28 Suppl: S500-16.
156. Willcox BJ, Willcox DC, Todoriki H, et al. Caloric restriction, the traditional okinawan diet, and healthy aging: The diet of the world's longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci 2007; 1114: 434-55.
157. Yamada T, Kadekaru H, Matsumoto S, et al. Prevalence of dementia in the older japanese-brazilian population. Psychiatry Clin Neurosci 2002; 56: 71-5.
158. Dodge HH, Katsumata Y, Todoriki H, et al. Comparisons of plasma/serum micronutrients between okinawan and oregonian elders: A pilot study. J Gerontol A Biol Sci Med Sci 2010; 65: 1060-7.
159. Ramesh BN, Rao TS, Prakasam A, Sambamurti K, Rao KS. Neuronutrition and alzheimer's disease. J Alzheimers Dis 2010; 19: 1123-39.
160. Shatenstein B, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc 2007; 107: 2091-9.
161. Siervo M, Arnold R, Wells JC, et al. Intentional weight loss in overweight and obese individuals and cognitive function: A systematic review and meta-analysis. Obes Rev 2011; 12: 968-83.
162. Siervo M, Nasti G, Stephan BC, et al. Effects of intentional weight loss on physical and cognitive function in middle-aged and older obese participants: A pilot study. J Am Coll Nutr 2012; 31: 79-86.
163. Carter CS, Leeuwenburgh C, Daniels M, Foster TC. Influence of calorie restriction on measures of age-related cognitive decline: Role of increased physical activity. J Gerontol A Biol Sci Med Sci 2009; 64: 850-9.
164. Levine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. J Clin Invest 2015; 125: 14-24.
165. Giem P, Beeson WL, Fraser GE. The incidence of dementia and intake of animal products: Preliminary findings from the adventist health study. Neuroepidemiology 1993; 12: 28-36.
166. Hallbook T, Ji S, Maudsley S, Martin B. The effects of the ketogenic diet on behavior and cognition. Epilepsy Res 2012; 100: 304-9.
167. Balietti M, Casoli T, Di Stefano G, Giorgetti B, Aicardi G, Fattoretti P. Ketogenic diets: An historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev 2010; 9: 273-9.
168. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004; 25: 311-4.
169. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent ac-1202 in mild to moderate alzheimer's disease: A randomized, double-blind, placebo- controlled, multicenter trial. Nutr Metab (Lond) 2009; 6: 31.
170. Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 2012; 3: 59.
171. Fuehrlein BS, Rutenberg MS, Silver JN, et al. Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets. J Clin Endocrinol Metab 2004; 89: 1641-5.
172. Brewer GJ. The risks of free copper in the body and the development of useful anticopper drugs. Curr Opin Clin Nutr Metab Care 2008; 11: 727-32.
173. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006; 63: 1085-8.
174. Pajonk FG, Kessler H, Supprian T, et al. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate alzheimer's disease. J Alzheimers Dis 2005; 8: 23-7.
175. Squitti R, Siotto M, Polimanti R. Low-copper diet as a preventive strategy for alzheimer's disease. Neurobiol Aging 2014; 35 Suppl 2: S40-50.
176. Loef M, Walach H. Copper and iron in alzheimer's disease: A systematic review and its dietary implications. Br J Nutr 2012; 107: 7-19.
177. Tyson CC, Nwankwo C, Lin PH, Svetkey LP. The dietary approaches to stop hypertension (dash) eating pattern in special populations. Curr Hypertens Rep 2012; 14: 388-96.
178. Wengreen H, Munger RG, Cutler A, et al. Prospective study of dietary approaches to stop hypertension- and mediterranean-style dietary patterns and age-related cognitive change: The cache county study on memory, health and aging. Am J Clin Nutr 2013; 98: 1263-71.
179. Morris MC, Tangney CC, Wang Y, et al. Mind diet slows cognitive decline with aging. Alzheimers Dement 2015; 11: 1015-22.
180. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. Mind diet associated with reduced incidence of alzheimer's disease. Alzheimers Dement 2015; 11: 1007-14.
181. Manheimer EW, van Zuuren EJ, Fedorowicz Z, Pijl H. Paleolithic nutrition for metabolic syndrome: Systematic review and meta-analysis. Am J Clin Nutr 2015 Aug 12 [Epub ahead of print].
182. Boraxbekk CJ, Stomby A, Ryberg M, et al. Diet-induced weight loss alters functional brain responses during an episodic memory task. Obes Facts 2015; 8: 261-72.
183. Utermann G. Alzheimer’s disease. The apolipoprotein e connection. Curr Biol 1994; 4: 362-5.